tetano
Editor, Senior Moderator
Cell Rep Med
. 2021 Mar 18;100230.
doi: 10.1016/j.xcrm.2021.100230. Online ahead of print.
A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
Ahmed O Hassan[SUP] 1 [/SUP], Friederike Feldmann[SUP] 2 [/SUP], Haiyan Zhao[SUP] 3 [/SUP], David T Curiel[SUP] 4 [/SUP], Atsushi Okumura[SUP] 5 [/SUP], Tsing-Lee Tang-Huau[SUP] 5 [/SUP], James Brett Case[SUP] 1 [/SUP], Kimberly Meade-White[SUP] 5 [/SUP], Julie Callison[SUP] 5 [/SUP], Rita E Chen[SUP] 1 3 [/SUP], Jamie Lovaglio[SUP] 2 [/SUP], Patrick W Hanley[SUP] 2 [/SUP], Dana P Scott[SUP] 2 [/SUP], Daved H Fremont[SUP] 3 6 7 [/SUP], Heinz Feldmann[SUP] 5 [/SUP], Michael S Diamond[SUP] 1 3 7 [/SUP]
Affiliations
Abstract
The deployment of a vaccine that limits transmission and disease likely will be required to end the Coronavirus Disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally-administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S) in the upper and lower respiratory tract of mice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor. Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged one month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induces neutralizing antibodies and T cell responses and limits or prevents infection in the upper and lower respiratory tract after SARS-CoV-2 challenge. As this single intranasal dose vaccine confers protection against SARS-CoV-2 in non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in humans.
. 2021 Mar 18;100230.
doi: 10.1016/j.xcrm.2021.100230. Online ahead of print.
A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
Ahmed O Hassan[SUP] 1 [/SUP], Friederike Feldmann[SUP] 2 [/SUP], Haiyan Zhao[SUP] 3 [/SUP], David T Curiel[SUP] 4 [/SUP], Atsushi Okumura[SUP] 5 [/SUP], Tsing-Lee Tang-Huau[SUP] 5 [/SUP], James Brett Case[SUP] 1 [/SUP], Kimberly Meade-White[SUP] 5 [/SUP], Julie Callison[SUP] 5 [/SUP], Rita E Chen[SUP] 1 3 [/SUP], Jamie Lovaglio[SUP] 2 [/SUP], Patrick W Hanley[SUP] 2 [/SUP], Dana P Scott[SUP] 2 [/SUP], Daved H Fremont[SUP] 3 6 7 [/SUP], Heinz Feldmann[SUP] 5 [/SUP], Michael S Diamond[SUP] 1 3 7 [/SUP]
Affiliations
- PMID: 33754147
- PMCID: PMC7969912
- DOI: 10.1016/j.xcrm.2021.100230
Abstract
The deployment of a vaccine that limits transmission and disease likely will be required to end the Coronavirus Disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally-administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S) in the upper and lower respiratory tract of mice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor. Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged one month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induces neutralizing antibodies and T cell responses and limits or prevents infection in the upper and lower respiratory tract after SARS-CoV-2 challenge. As this single intranasal dose vaccine confers protection against SARS-CoV-2 in non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in humans.